References

Re/erences

References

1. Gubler, D. J. (1997) Epidemic dengue/dengue haemorrhagic fever: A global public health problem in the 21st century. WHO Dengue Bulletin 21, 1-15.

2. Gubler, D. 1. (1998) Dengue. In: Epidemiology of arthropod-borne viral disease (Monath, T. P. M., Ed.), pp, 223-260, Boca Raton (FL): CRC Press.

3. George, R, and Lum, L. C. S. (1997) Clinical spectrum of dengue infection. In: Dengue and Dengue Hemorrhagic Fever (Gubler, D. J., and Kuno. G., Eds.), pp, 89-113, CAB International, UK.

4. Monath, T. P. (1994) Dengue: The risk to developed and developing countries. Proc. Natl. Acad. Sci. USA 91, 2395-2400.

5. Bielefeldt-Ohmann, H. (1997). Pathogenesis of dengue virus diseases: missing pieces in the jigsaw. TrendsMicrobiol. 5,409-413.

6. Morens, D. M. (1994) Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin. Infect. Dis. 19,500-512.

7. Gubler D. J. (1993) Dengue and dengue haemorrhagic fever in the Americas. In: WHO, Regional Office for SE Asia, New Delhi, Monograph. SEARO; 22, 9-22.

8. Lanciotti, R S., Lewis, 1. G., Gubler, D. 1., and Trent, D. W. (1994) Molecular evolution and epidemiology of dengue-3 viruses. J. Gen. Virol. 75,65-75.

9. Qiu, F. X., Gubler, D. J., Liu, J. C., Chen, and Q. Q. (1993) Dengue in China: a clinical review. Bull. WHO 71, 349-59.

10. Anonymous. (1994) The dengue situation in Singapore. Epidemiol. Bull. 20,31-3.

11. Rao, C. V. R M. (1987) Dengue fever in India. Indian J. Pediatr. 54, 11-4.

12. Rao, C. V. R M., Bagchi, S. K., Pinto, B. D., Dkal, M. A., Bharadwaj, M., and Shaikh, B. H. (1985) The 1982 epidemic of dengue fever in Delhi. Indian J. Med Res. 82,271-5.

13. Kabra, S. K., Verma, I. c., Arora, N. K., Jain, Y., and Kalra, V. (1992) Dengue haemorrhagic fever in children in Delhi. Bull. WHO 70, 105-8.

14. Sharma, P. L., and Sood, O. P., Eds. (1996) Round table conference series-dengue outbreak in Delhi: 1996.Gurgaon, India: Ranbaxy Science Foundation.

123

Rcfercnces

15. Gubler, D. J., Kuno, G., Sather, G. E., Valez, M., and Oliver, A. (1984) Mosquito cell and specific monoclonal antibodies in surveillance for dengue viruses. Am. J. Trop. Med Hyg. 33, 158-65.

16. Rigau-Perez. J. G., Clark, G. G., and Gubler, D. 1. (1998) Dengue and dengue hemorrhagic fever. Lancet 352,971-977.

17. da Fonseca, B. A, and Fonseca, S. N. (2002) Dengue virus infections. Curro Opin. Pediatr. 14,67-71.

18. Gubler, D. J. (1994) Dengue viruses. In: Encyclopedia of Virology (Webstar, R. G., and Granoff, A, Eds.), pp. 324-331.

19. Guzman, M. G., and Kouri, G. (2002) Dengue: an update. Lancet Infect. Dis. 2(1), 33-42.

20. Kurane, 1., Meager, A, and Ennis, F. A, (1989) Dengue virus-specific human T cell clones: serotype cross-reactive proliferation, interferon gamma production, and cytotoxic activity. J. Exp. Med 170,763-775.

21. Bukowski, J. F., Kurane, 1., Lai, C-J., Bray, M., Falgout, B., and Ennis, F. A., (1989) Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J. Virol. 63, 5086-5091.

22. Kurane, 1., Innis, B. L., Nimmannitya, S., Nisalak, A, Rothman, A. C., Livingston, P. G., Janus, J., and Ennis, F. A (1990) Human immune responses to Dengue viruses. Southeast Asian J. Trop. Med Public Health 21, 658-662.

23. Holmes, E. C., Bartley, L. M., and Garnett, G. P. (1998) The emergence of dengue: past, present and future. In: Emerging Infections (Krause, R. M., Eds.), pp. 301-325, Academic Press, San Diego, CA

24. Kurane, 1., and Francis, A E. (1997) Immunopathogenesis of dengue virus infections. In: Dengue and Dengue hemorrhagic Fever (Gubler, D. J., and Kuno, G. K., Eds.), pp, 273-290, CAB International UK.

25. Henchal, E. A. and Putnak, J. R. (1990) The Dengue Viruses. Clinical Microbiology Reviews 3, 376-396.

26. Kuhn, R. J., Zhang, W., Rossmann M. G., Pletnev, S. V., Corver, J., Lenches, E., Jones, C. T., Mukopadhyay, S., Cipman, P. R., Strauss, E. G., Baker, T. S., and Strauss, J. H. (2002) Structure of Dengue virus: Implications for flavivirus organization, maturation and fusion. Cell 108, 717-725.

27. Zhao, B., Mackow, E., Buckler-White, A, Markoff, L., Chanock, R. F., Lai, c.-J., and Yoshihiro Makino. (1986) Cloning Full Length Dengue Type 4 Viral DNA Sequences: Analysis of Clones Coding for Structural Proteins. Virology 155, 77-88.

124

Rekrenccs

28. Wengler, G. and Wengler, G. (1989) Cell associated West Nile Flavivirus is covered with E+PrM protein heterodimers which are destroyed and reorganised by proteolytic cleavage during virus release. J. Virol. 63,2521-2526.

29. Konishi, E. and Mason, P. W. (1993) Proper maturation of the Japanese Encephalitis Virus envelope glycoprotein requires cosynthesis with the Premembrane protein. J. Virol. 67, 1672-1675.

30. Guirakhoo, F., Bolin, R A., and Roehrig, 1. T., (1992); The Murray Valley Encephalitis Virus prM protein confers acid resistance to virus particles and alters the expression of eptiopes within the R2 domain ofE glycoprotein. Virology 191, 921-931.

31. Chambers, T. J., Hahn, C. S., Galler, R, and Rice, C. M. (1990) Flavivirus genome organization, expression and replication. Annu. Rev. Microbiol. 44, 649-688.

32. Chang, G.-J. (1997) Molecular biology of dengue viruses. In: Dengue and Dengue hemorrhagic Fever (Gubler, D. 1., and Kuno, G. K., Eds.), pp, 175-198, CAB International UK.

33. Hahn, Y. S., Daller, R, Hunkapiller, T., Dalrymply, J. M., Strauss, J. H., and Strauss, E. G. (1988) Nucleotide sequence of Dengue 2 RNA and comparison of the encoded proteins with those of other flaviviruses. Virology 162, 167-180.

34. Blok, J., McWilliam, S. M., Butler, H. C., Gibbs, A. J., Weiller, G., Herring, B. L., Hemsley, A. c., Aaskov, 1. G., Yoksan, S., and Bhamarapravati,N. (1992) Comparison of a Dengue-2 virus and its candidate vaccine derivative: sequence relationships with the flaviviruses and other viruses. Virology 187, 573-590.

35. Mandl, c., Heinz, F. x., and Kunz, C. (1988) Sequence of the structural proteins of Tick-Borne Encephalitis virus (western sub-type) and comparative analysis with other flaviviruses. Virology 166, 197-205.

36. Rothman, A. L. (1997) Viral pathogenesis of dengue infections. In: Dengue and Dengue hemorrhagic Fever (Gubler, D. 1., and Kuno, G. K., Eds.), pp, 245-271, CAB International UK.

37. Chen, Y., Maguire, T., and Hileman, R. E. (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3, 866-871.

38. Crill, W. D., and Roehrig, D. T. (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorbtion to Vero cells. J. Virol. 73,81-89.

39. Heinz, F. x., and Allison, S. L. (2001) The machinery for flavivirus fusion with host cell membranes. Curro Opin. Microbiol. 4,450-455.

125

References

40. Rodhain, F., and Rosen, L. (1997) Mosquito vectors and dengue virus-vector relationships. In: Dengue and Dengue hemorrhagic Fever (Gubler, D. I., and Kuno, G. K., Eds.), pp, 45-60, CAB International UK.

41. Hayes, E. B., and Gubler, D. I. (1992) Dengue and dengue hemorrhagic fever. Pediat. InJec. Dis. J. 11, 311-317.

42. Clarke, T. (2002) Dengue virus: Break-bone fever. Nature 416, 672-674.

43. Chambers, T. 1., Tsai, T. F., Pervikov, Y., and Monath, T. P. (1997) Vaccine development against dengue and Iapanese encephalitis: report of a World Health Organization meeting. Vaccine 15, 1494-1502.

44. Bhamarapravati, N., Yoksan, S., Chayaniyayothin, T., Angsubphakorn, S., and Bunyaratvej, A. (1987) Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull. World Health Org. 65, 189-195.

45. Bhamarapravati, N. and Yoksan, S. (1989) Study of bivalent dengue vaccine in volunteers. The Lancet 1, 1077.

46. Vaughn, D. W., Hoke, C. H., Yoksan, S., LaChance, R, Innis, B. L., Rice, R M., and Bhamarapravati, N. (1996) Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14, 329-336.

47. Bhamarapravati, N., and Yoksan, S. (1997) Live attenuated tetravalent dengue vaccine. In: Dengue and Dengue hemorrhagic Fever (Gubler, D. 1., and Kuno, G. K., Eds.), pp, 367-377, CAB International UK.

48. Putnak, R, Barvir, D. A, Burrous, J. M., Dubois, D. R., D'Andrea, V. M., Hoke,C. H., Sadoff, J. C., and Eckels, K. H. (1996) Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenecity and protection in mice and rhesus monkeys. J. Injec. Dis. 174, 1176-1184.

49. Venugopal, K., and Gould, E. A (1994) Towards a new generation of flavivirus vaccines. Vaccine 12, 966-975.

50. Kanesa-thasan, N., Sun, W., Kim-Akn, G., Albert, S. V., Putnak, R I., King, A, Raengsakulsrach, B., Christ-Schmidt, H., Gilson, K., Zahradnik, 1. M., Vaughn, D. W., Innis, B. L., Saluzzo, I.-F., and Hoke, Ir. C. H. (2001) Safety and immunogenecity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19, 3179-3188.

51. Halstead, S. B., Diwan, A R, Marchette, N. J., Palumbo, N. E., and Srisukonth, L., (1984) Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. I. Attributes of uncloned virus at different passage levels. Am. J. Trop. Med Hyg. 33, 654-665.

126

52. Butrapet, S., Huang, C. Y. H., Pierro, D. I., Bhamarapravati, N., Gubler, D. I., and Kinney, R M. (2000) Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and non structural protins 1 and 3. J. Viro!. 74, 3011-3019.

53. Schoepp, R I., Beaty, B. I. and Eckels, K H. (1991) Infection of Aedes albopichts and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marlcer of human attenuation. Am. J. Trop. Med Hyg, 45, 202-210.

54. Alvarez, M., Guzman, M. G., Pupo, M, Morier, L., Bravo, 1., and Rodriguez, R (2001) Study of biologic attributes of Cuban dengue 2 virus after serial passage in primary dog kidney cells. Int. J. Infec. Dis. 5, 35-39.

55. Brandt, W. E. (1990) Development of Dengue and Japanese encephalitis vaccines. J. Infec. Dis. 162, 577-583.

56. Brandt, W. E. (1988) Current approaches to the development of dengue vaccines and related aspects of the molecular biology of flaviviruses. J. Infec. Dis. 157, 1105-1111.

57. Innis, B. L., Eckels, K. H., Kraiselburd, E., Dubois, D. R, Meadors, G. F., Gubler, D. J., Burkr, D. S., and Bancroft W. H. (1988) Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J. Infec. Dis. 33, 876-880.

58. Eckels, K H., Scott, R M., Bancroft; W. H., Brown, J., Dubois, D. R, Summers, P. L., Russell, P. K., and Halstead, S. B. (1984) Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am. J. Trop. Med Hyg. 33, 684-689.

59. McKee, K T. Jr., Bancroft, W. H., Eckels, K. H., Redfield, R R, Summers, P. L., and Russell, P. K (1987) Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am. J. Trop. Med Hyg. 36, 435-442.

60. Marchette, N. J., Dubois, D. R., Larsen, L. K, Summers, P. L., Kraiselburd, E. G., Gubler, D. J., and Eckels, K. H., (1990) Preparation of a Dengue 4 (341750 Carib) Virus Vaccine. I. Pre-Clinical Studies. Am. J. Trop. Med. Hyg. 43,212-218.

61. Hoke, C. H. Jr, Malinoski, F. J., Eckels, K H., Scott, R. M., Dubois, D. R, Summers, P. L., Simms, T., Burrows, J. Hasty, S.E., and Bancroft,W. H. (1990) Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am. J. Trop. Med Hyg. 43, 219-226.

62. Kapoor, M., Zhang, L., and Padmanabhan, R (1995) Synthesis and charaterization of an infectious dengue virus type-2 RNA genome. (New Guinea C strain). Gene 162, 175-180.

127

Re/erences

63. Kinney, R M., Butrapet S., Chang, G.-J. J., Tsuchiya, K. R, Roehrig, J. T., Bhamarapravati, N., and Gubler, D. J. (1997) Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230,300-308.

64. Lai, C.-I., Zhao, B., Hori, H., and Bray, M. (1991) Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc. Natl. Acad. Sci. USA. 88,5139-5143.

65. Bray, M. and Lai, C.-I. (1991) Construction ofintertypic chimeric dengue viruses by substitution of structural protein genes. Proc. Natl. Acad. Sci. USA. 88, 10342-10346.

66. Chen, W., Kawano, H., Men, R., Clark, D., and Lai, C.-J. (1995) Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J. Virol. 69,5186-5190.

67. Huang. C. Y.-H., Butrapet, S., Pierro, D. J., Chang, G.-J. J., Hunt, A. R, Bhamarapravati, N., Gubler, D. J., and Kinney, R M. (2000) Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J. Virol. 74,3020-3028.

68. Bray, M., Men, R, and Lai, C. 1. (1996) Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J. Virol. 70,4162-4166.

69. Guirakhoo, F., Weltzin, R., Chambers, T. J., Zhang, Z-x., Soike, K., Ratterree, M., Arroyo, J., Georgakopoulos, K., catalan, J., and Monath, T. P. (2000) Recombinant chimeric yellow fever-dengue fever type 2 virus is immunogenis and protective in nonhuman primates. J. Viro/. 74,5477-5485.

70. Monath, T. P., Arroyo, J., Levenbook, I., Zhang, Z. X., Catalan, J., Draper, K., and Guirakhoo, F. (2002) Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J. Virol. 76, 1932-43.

71. Hanley, K. A., Lee, J. J., Blaney, 1. E. Jr., Murphy B. R and Whitehead, S. S. (2002) Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J. Virol. 76, 525-531.

72. Pryor, M. J., Gulano, R C., Lin, B., Davidson, A. D. and Wright, P. J. (1997) Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins. J Gen Virol. 79,2631-2639.

128

References

73. Men, R, Bray, M., Clark, D., Chanock, R M., and Lai,C. J. (1996) Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenecity in the rhesus monkeys. J. Virol. 70, 3930-3937.

74. Bray, M., Zhao, B. T., Markoff, L., Eckels, K. H., Chanock, R M., and Lai, C. J. (1989) Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructura1 protein NS 1 are protected against fatal dengue virus encephalitis. J. Virol. 63, 2853-2856.

75. Men, R H., Bray, M., Lai, C. J. (1991) CaIboxy-terminaily truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. J. Virol. 65, 1400-1407.

76. Men, R, Wyatt, L., Tokimatsu, I., Arakaki, S., Shameem, G., Elkins, R, Chanock, R, Moss, B. and Lai, C.-J. (2000) Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 challenge. Vaccine 18, 3113-3122.

77. Bray, M., and Lai, C.-J. (1991) Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 185,505-508.

78. Tighe, H., Corr, M., Roman, M., and Raz, E. (1998) Gene vaccination: Plasmid DNA is more than just a blueprint. Immun. Today 19, 89-97.

79. Fynan, E. F., Webster, R G., Fuller, D. H., Haynes, J. R, Santoro, J. c., and Robinson, H. L. (1993) DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA. 90,11478-11482.

80. Chang, G. J., Davis, B. S., Hunt, A. R, Holmes, D. A., and Kuno, G. (2001) Flavivirus DNA vaccines: current status and potential. Ann. N. Y. Acad Sci. 951, 272-85.

81. Polo, J. M., and Dubensky, T. W. Jr. (1998) DNA vaccines with a kick. Nature Biotech. 16,517-518.

82. Kochel, T., Wu, S.-1., Raviprakash, K, Hobart, P., Hoffinan, S., Porter, K., and Hayes, C. (1997) Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 15, 547-552.

83. Kochel, T. J., Raviprakash, K, Hayes, C. G., Watts, D. M., Russell, K. L., Gozalo, A S., Phillips, I. A., Ewing, D. F., Murphy, G. S., Porter, K R (2000) A dengue virus serotype-l DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 18, 3166-73.

129

Referel1ces

84. Churdboonchart, V., Bhamaraparvati, N., Peampramprecha, S., and Srinavin, S. (1991) Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med Hyg. 44,481-493.

85. Kaufman, B. M., Summers, P. L., Dubois, D. R., and Eckels, K. H. (1987) Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med Hyg. 36,427-434.

86. Feighny, R., Burrows, J., McCown, J., Hoke, C., and Putnak, R. (1992) Purification of native dengue 2 viral proteins and the ability of purified proteins to protect mice. Am. J. Trop. Med Hyg. 47,405-412.

87. Staropoli, I., Frenkiel, M.-P, Megret, F. and Deubel, V. (1997) Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 15, 1946-1954.

88. Roehrig, J. T., Johnson, A. J., Hunt, A. R., Bolin, R. A. and Chu, M. C. (1990) Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic confonnation. Virology 177, 668-675.

89. Roehrig, J. T., Hunt, A. R., Johnson, J. 1., and Hawkes, R. A. (1989) Synthetic peptides derived from the deduced amio acid sequence of the E-glycoprotein of Murray Encephalitis virus elicit antiviral atibody. Virology 171,49-60.

90. Baneyx, F. (1999) Recombinant protein expression in Escherichia coli. Curro Opin. Biotechnol. 10,411-421.

91. Simmons, M., Nelson, W. M., Wu, S. J., and Hayes, C. G. (1998) Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med Hyg. 58, 655-62.

92. Simmons, M., Murphy, G. S., and Hayes, C. G. (2001) Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med Hyg. 65, 159-161.

93. Sugrue, R. J., Cui, T., XU, Q., Fu, J., and Chan, Y. C. (1997) The production of recombinant dengue virus E protein using Escherichia coli and Pichia pastoris. J. Virol. Methods 69, 159-169.

94. Delenda, C. Frenkiel, M. P., and Deubel, V. (1994) Protective efficacy in mice of a secreted fonn of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells. Arch. Virol. 139, 197-207.

95. Staropoli, I., Clement, J. M., Frenkiel, M. P., Hofnung, M., and Deubel, V. (1996) Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein. J. Virol. Methods 56, 179-189.

130

References

96. Putnak, R, Feighny, R, Burrous, J., Cochran, M., hackett, C., Smith, G., and Hoke, C. (1991) Dengue-l virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am. J. Trop. Med Hyg. 45, 159-167.

97. Kelly, E. P., Greene, J. J., King, A. D., and Innis, B. L. (2000) Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18,2549-59.

98. Sugrue, R J., Fu, J., Howe, J., and Chan, Y.-C. (1997) Expression of the dengue viral structural proteins in Pichia pastoris leads to the generation of virus-like particles. J. Gen. Viral. 78, 1861-1866.

99. Vassileva, A., Chugh, D. A., Swaminathan, S. and Khanna, N. (2001) Effect of copy number on the expression levels of Hepatitis B surface antigen in the methylotrophic yeastPichia pastoris. Protein Exp. Purif. 21, 71-80.

100. Ogata, K., Nishikawa, H., and Ohsugi, M. (1969) A yeast capable of utilizing methanol. Agric. BioI. Chem. 33, 1519-1520.

101. Siegel, R S., and Brierley, R. A. (1989) Methylotrophic yeast Pichia pastoris produced in high-cell-density fermentations with high cell yields as vehicle for recombinant protein production. Biotechnol. Bioeng. 34,403-404.

102. Cregg, J. M. (1999) Expression in the methylo trophic yeast Pichia pastoris. In: Gene Expression Systems: Using nature for the Art of Expression (Fernandez, J. M., and Hoemer, J. P., Eds.), pp. 1-5. Academic Press, San Diego, CA.

103. Walker, G. M. (1998) Yeast: Physiology and Biotechnology. pp. 231-233. John Wiley & Sons, UK.

104. Gleeson, M. A. and Sudbery, P. E. (1998) The methylotrophic Yeasts. Yeast 4, 1-15.

105. Couderc, Rand Baratti, J. (1980) Oxidation of methanol by the yeast Pichia pastoris: purification and properties of alcohol oxidase. Agric. BioI. Chem. 44, 2279-2289.

106. Roggenkamp, R, Janowicz, Z., Stanikowski, B., and Hollenherg, C. P. (1984) Biosynthesis and regulation of the peroxisomal methanol oxidase from the methylotrophic yeast Hansenula polymorpha. Mol. Gen. Genet. 194, 489-493.

107. Cregg, J. M., Madden, K. R, Barringer, K. J., Thill, G. P., and Stillman, C. A. (1989) Functional characterization of the two alcohol oxidase genes from the yeastPichiapastoris.Mol. Cell. BioI. 9,1316-1323.

131

Rejerences

108. Tschopp, J. F., Brust, P. F., Cregg, J. M., Stillman, S. A, and Gingeras, T. R. (1987) Expression of the lacZ gene from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res. 15, 3859-3876.

109. Ellis, S. B., Brust, P. F., Koutz, P. J., Waters, A F., Harpold, M. M. and Gingeras, T. R (1985) Isolation of alcohol oxidase and two other methanol regulatable genes from the yeast Pichia pastoris. Mol. Cell. Bioi. 5, 1111-1121

110. Cregg, J. M, and Madden, K R (1988) Development of the methylotrophic yeast, Pichia pastoris, as a host system for the production of foreign proteins. Dev. Ind. Microbiol. 29,33-41.

Ill. Cereghino, J. L., and Cregg, J. M. (2000) Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 24,45-66.

112. Clare, J. J., Rayment, F. B., Ballantine, S. P., Sreekrishna, K, Romanos, M. A (1991) High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (N }j 9(5), 455-60.

113. Montesino, R., Garcia, R, Quintero, O. and Cremata, J. A (1998) Variation in N-linked oligosaccharide structures on heterologous proteins secreted by the methylotrophic yeastPichiapastoris. Prot. Expr. Purif. 14, 197-207.

114. Wegner, E. H. (1983) Biochemical conversions by yeast fermentation at high cell densities. US Patent 441 4329.

115. Cregg, J. M., Barringer, K J., Hessler, A Y. and Madden, K. R (1985) Pichia pastoris as a host system for transformations. Mol. Cell. Bioi. 5(12),3376-3385.

116. Higgins, D. R., and Cregg, J. M. (1998) Inroduction to Pichia pastoris. In: Pichia Protocols (Higgins, D. R, and Cregg, J. M., Eds.), pp, 1-15, Humana Press, Totowa, New Jersey.

117. Trent, D. W., Kinney, R M., and Huang, C. Y.-H. (1997) Recombinant dengue vaccines. In: Dengue and Dengue hemorrhagiC Fever (Gubler, D. J., and Kuno, G. K., Eds.), pp, 379-403, CAB International UK.

118. Hermida, L., Rodriguez, R, Lazo, L., Lopez, C., Marquez, G., Paez, R, Suarez, C., Espinosa, R, Garcia, J., Guzman, G., and Guillen, G. (2002) A recombinant envelope protein from Dengue virus purified by IMAC is bioequivalent with its immune-affinity chromatography purified counterpart. J Biotechnol. 94,213-216.

119. Fonseca, B. A L., Pincus, S., Shope, R E., Paoletti, E., and Mason, P. W. (1994) Recombinant vaccinia viruses co-expressing dengue-l glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 12,279-285.

132

References

120. Delenda, c., Staropoli, 1, Frenkiel, M.-P., Cabanie, L. and Deubel, V. (1994) Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. J. Gen. Virol. 75, 1569-1578.

121. Deubel, V., Bordier, M., Megret, F., Gentry, M K., Schlesinger, I. I., and Girads, M. (1991) Processing, secretion, and immunogenecity of carboxy terminally truncated dengue-2 virus envelope proteins expressed in insect cells by recombinant baculoviruses. Virology 180, 442-447.

122. Kozak, M. (1987) An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15,8125-8148.

123. Arora, D., Chauhan, A. K., and Khanna, N. (1998) Easy PCR screening of Pichia pastoris transformants. Cell. Mol. Bioi. Lett. 3,21-24.

124. Lamelli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.

125. Bradford, M. M. (1976) A rapid and sensitive method for the quantitaion of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72,248-254.

126. Pupo-Antunez, M., Rodriguez, R, Alvarez, M., Amin, N., Rodriguez, H., Otero, A., and Guzman, G. (2001) Development of a monoclonal antibody specific to a recombinant envelope protein from dengue viru type 4 expressed in Pichia pastoris. Hybridoma 20, 35-41.

127. Katakura, Y, Zhang, W., Zhang, G., Omasa, T., Kishimoto, M., Goto, Y, and Suga, K.-1 (1998) Effect of methanol concentration on the production of human fh-glycoprotein I domain V by a recombinant Pichia pastoris: A simple system for the control of methanol concentration using a semi-conductor gas sensor. J. ferment. Bioeng. 86, 482-487.

128. Petty, K. I. (1996) Metal-chelate affinity chromatography. In: Current protocols in Molecular Biology (Ausubel, F. M., brent, R, Kingston, R E., Moore, D. D. Sedman, J. G., Smith, J. A., and Struhl, K., Eds.), John Wiley and Sons, New York.

129. Cregg, J. M., Tschopp, J. F., Stillman, C., Siegel, R, Aleong, M., Craig, W. S., Buckholz, R. G., Madden, K. R., Kellaris, P. A., Davis, G. R, Smiley, B. L., Cruze, I., Torregrossa, R., Velicelibi, G., and Thill, G. P. (1987) High level expression and efficient assembly of hepatitis B surface antigen in the methylotrophic yeast, Pichia pastoris. Bio/Technology 5,479-485.

130. Murphy, B. R, and Chanock, R. M. (1996) Immunization against virus disease. In: Fields Virology 3rd edition (Fields, B. N., Knipe, D. M., Howley, P. M. et aI., Eds.), pp, 467-497. Lippincott-raven, Philadelphia.

133

References

131. Gamelkoorn, G. J. (1991) case study: Hepatitis B vaccine: a product ofr-DNA techniques. In: Biotechnological innovations in health care (Turnoc~ G., Ed.), pp, 141-164, Butterworth-Heinemann.

132. Wang, S., He, R, Anderson, R (1999) prM- and cell-binding domains of the dengue virus E protein. J. Viro!. 73,2547-2551.

133. Roehrig, J. T. (1997) Immunochemistry of dengue viruses. In: Dengue and Dengue hemorrhagic Fever (Gubler, D. J., and Kuno, G. K., Eds.), pp, 199-219, CAB International UK.

134. Eckels, K. H., Dubois, D. R, Summers, P. L., Schlesinger, J. J., Shelly, M., Cohen, S., Zhang, Y.-M., Lai, C.-J., Kurane, I., Rothman, A., Hasty, S., and Howard, B. (1994) Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and non structural proteins: evidence of priming and partial protection. Am. J. Trop. Med Hyg. 50,472-478.

135. Delpeyroux, F., Peillon, N., Blondel, B., Crainic, R., and Streec~ R E. (1988) Presentation and immunogenicity of the hepatitis B surface antigen and a poliovirus neutralization antigen on mixed empty envelope particles. J. Virol. 62, 1836-1839.

136. Michel, M.-L., Mancini, M., Schlienger, K., and Tiollais, P. (1993) Recombinant hepatitis B surface antigen as a carrier of human deficiency virus epitopes. Res. Virol. 144,263-267.

137. Gordon, D. M., mcGovern, T. W., Krzych, U., Cohen J. C., Schneider, I., Lachance, R., Heppner, D. G., Yuan, G., Hollingdale, M., Slaoui, M., Hauser, P., Voet, P., Sadoff, J. C., and Ballou, W. R. (1995) Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infec. Dis. 171, 1576-1585.

138. Craig, W. S., and Siegel, R S. (1989) Purificaition of hepatitis proteins. European Patent Application No 0 337 492 AI.

l34